Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and five have issued a strong buy recommendation on the company.
Several research analysts recently commented on GLX shares. Citizens Jmp raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th. ATB Cormark Capital Markets lowered shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th. Finally, Citigroup upgraded shares of Bradmer Pharmaceuticals to a “hold” rating in a research report on Tuesday, February 24th.
Read Our Latest Analysis on GLX
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- REVEALED: Something Big Happening Behind White House Doors
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
